LAG3 and breast carcinoma: In breast cancer cohorts, LAG-3 expression is associated with markers of T-cell exhaustion and co-inhibitory molecules such as TIGIT and PD-L1, indicating its potential role in regulating T-cell dysfunction and impairing anti-tumor immune responses [152].